Bolden named incoming ad director at GlaxoSmithKline

Andy Bolden, the former business and client services director at Mediaedge:cia, is set to replace GlaxoSmithKline's outgoing UK ad director John Blakemore when he retires in June.

Bolden, who has 28 years' experience in the media industry, joins GSK at the end of April. He will be responsible for GSK's £40 million media budget, which is split between household brands including Lucozade and Ribena.

Bolden will work with GSK's marketing teams and with its media agency, MediaCom, to develop the best plans and prices for the company. He will also represent GSK on industry committees.

A GSK spokesman said: "Andy's job is about us getting the biggest bang for our advertising buck."

Bolden began his career at Young & Rubicam as a TV buyer. He then joined CIA where he worked with clients including Nationwide, Wrigleys and Cussons.

Last year, Bolden was made the head of one of four business groups established after the merger with Mediaedge. He left shortly afterwards to work at Brand Connection.

Blakemore began his career with J.Walter Thompson in 1966. He joined SmithKline Beecham in 1991 and saw the company merge with Glaxo Wellcome ten years later.

Blakemore has also been part of the TV action group in the Incorporated Society of British Advertisers. He will give up this role on his retirement.